Cargando…
P1276: HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELL FOR THE TREATMENT OF STEROID-REFRACTORY AGVHD: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL
Autores principales: | Liu, Dai-Hong, Yao, Chen, Yang, Donglin, Dou, Liping, Hou, Xiaoqiang, Qian, Kun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430605/ http://dx.doi.org/10.1097/01.HS9.0000971992.86050.85 |
Ejemplares similares
-
Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease
por: Donadel, Camila Derminio, et al.
Publicado: (2023) -
Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021) -
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II–IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial
por: Yang, Donglin, et al.
Publicado: (2023) -
AGREEMENT No K1276/AB
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2006) -
Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)